NCPA Past President Sal D’Angelo was credited with the expression, “Get into politics or get out of pharmacy.” That was nearly 50 years ago when the National Community Pharmacists Association (NCPA) held its first legislative conference − one of the first such events in the profession. Even though times have changed, the importance of that message for pharmacy owners has not.
News: Legal & Regulatory
On December 18, South Carolina Governor Henry McMaster issued two executive orders regarding the opioid epidemic. As one result, by March 1, the organization that provides insurance for the state’s public employees will voluntarily adopt a five-day limitation on initial opioid prescriptions for acute and post-operative needs.
As of Monday, January 1, 2018, prescribers in Nevada must begin their controlled substance reporting in ASAP 4.2A format. You can find the specifications for 4.2A reporting on page 4 of the Nevada Data Submission Dispenser Guide, under the heading "Upload Specifications."
As of Friday, December 29, 2017, prescribers in Ohio must include the first four alphanumeric characters (e.g., M16.5) of the diagnosis code (ICD-10), or the full procedure code (Current Dental Terminology - CDT), on all opioid prescriptions, which will then be entered by pharmacies into OARRS (Ohio Automated Rx Reporting System).
Effective January 1, 2018, the Nebraska Prescription Drug Monitoring Program (PDMP) requires that all prescriptions be reported. You can find reporting requirements in the Nebraska Dispenser's Implementation Guide (version 3.6).
To allow sufficient time for pharmacies to make the changes necessary to submit prescription information in ASAP 4.2A format, Oregon's Prescription Drug Monitoring Program (PDMP) will continue to accept submissions using ASAP 4.1 and 4.2 until January 1, 2018.
As of July 7, 2017, pharmacies in West Virginia are required to report Gabapentin as a Drug of Concern to the state’s Controlled Substance Monitoring Program (CSMP).
Beginning August 9, 2017, Schedule V controlled substances must be reported to the Arizona Controlled Substances Prescription Monitoring Program (PMP), in addition to already reported Schedule II, III and IV drugs.
Effective Tuesday, August 15, 2017, the Colorado Prescription Drug Monitoring Program (CO PDMP) will change how prescription data submissions are reported by moving to Appriss® PMP AWARxE™.
In May, the Massachusetts Department of Public Health released a requirement that Gabapentin and its chemical equivalents be included as an "additional" Schedule VI drug for PMP reporting.